Novavax Raises Full-Year Adjusted Revenue Forecast, Bets On Strength Of Vaccine Supply Partnerships

Reuters (8/6, Sunny) reports, “Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan’s Takeda, sending its shares surging 15%.” Novavax “has been shifting its focus to commercializing vaccine candidates through partnerships.” The biotech “relies on revenue from its licensing deal with French drugmaker Sanofi and vaccines in development, including a COVID-flu combination shot and for bird flu that is currently undergoing lab testing.” Novavax “expects its 2025 adjusted revenue to be between $1 billion and $1.05 billion, up from $975 million to $1.03 billion forecast earlier.”